Interim data show substantial improvements in 'Good On” time compared to other oral CD/LD therapiesCREXONT delivered ...
When the hospital germ Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to ...
Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study ...
“It was a really hard sell,” recalls Druker, an oncologist and CEO of the Oregon Health & Science University Knight Cancer Institute, decades on. There were seemingly valid concerns at the time, he ...
SNS Insider Reports Steady Growth in the Parkinson’s Disease Treatment Market, Expanding from $5.37 Billion in 2023 to $8.75 Billion by 2032, Supported by Aging Populations, Breakthrough ...
A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback